title: Informed prostate cancer risk-adjusted testing: a new paradigm.
abstract: • Currently there is significant confusion and polarisation about prostate cancer screening for both patients and physicians alike. • We propose a risk-adjusted testing programme, which would lead to fewer patients who need to be tested and treated to save a life and also eliminate inappropriate prostate-specific antigen testing in the elderly and patients with severe co-morbidities where there is no clear benefit.
authors.affiliation: St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia.
authors.forename: Phillip D
authors.initials: PD
authors.lastname: Stricker
authors.forename: Mark
authors.initials: M
authors.lastname: Frydenberg
authors.forename: Andrew
authors.initials: A
authors.lastname: Kneebone
authors.forename: Samarth
authors.initials: S
authors.lastname: Chopra
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D055088:Early Detection of Cancer / Q000379:methods*; D014943:Global Health; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen